跳至主要内容
临床试验/NCT00870324
NCT00870324已完成不适用

OptiSense Performance in Detecting Atrial Episodes in CRMD Device Patient Population

Abbott Medical Devices2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2009年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
2
主要终点
The primary endpoint of the study is the difference in duration between the device-determined time in AF (Device Duration) and the ECG-determined time in AF (ECG Duration).

研究概览

简要总结

The SENSE-AF study aims to determine the performance of the OptiSense lead in sensing fine episodes of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) and rejecting Far-Field R Wave (FFRW). The performance of the lead will be measured as a difference in device-determined time in AT/AF and surface-ECG determined time in AT/AF. This measurement will be compared to the control group which will be randomized to receive SJM's Tendril™ RA leads.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who meets current ICD or CRT-D implant indications and receive a St. Jude Medical ICD/CRT-D
  • Patients who will receive a new St. Jude Medical OptiSense or Tendril RA lead as part of their device implant

排除标准

  • Patients with a history of Permanent or Persistent AF
  • Patient's life expectancy is less than 12 months.
  • Patient is pregnant.
  • Patient's age at enrollment is less than 18 years.

结局指标

主要结局

The primary endpoint of the study is the difference in duration between the device-determined time in AF (Device Duration) and the ECG-determined time in AF (ECG Duration).

时间窗: 3 months post-implant

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验